“The primary outcome of this trial is a comparison of the progression-free survival (PFS) between the afatinib monotherapy and combination therapy of afatinib plus HAD-B1 for patients with locally advanced or metastatic EGFR-mutationpositive NSCLC” has been corrected to “The primary measurement is comparison of starting dose maintenance rate for afatinib and disease adjustment rate (DCR) at 16 weeks in accordance with RECIST 1.1 of Afatinib + HAD-B1 combined group and afatinib monotherapy group.” This evidence concerns the gene EGFR and non-small cell lung carcinoma.